BIOMAT Database Logo BIOMAT Database Logo

High-risk metastatic gestational trophoblastic disease. 1985

A N Gordon, and D M Gershenson, and L J Copeland, and P B Saul, and J J Kavanagh, and C L Edwards

The clinical course of 61 patients with high-risk metastatic gestational trophoblastic disease was reviewed. Currently, 34 patients (56%) are alive and in complete remission. The survival rate after full-term pregnancy was significantly worse than after any other type of antecedent pregnancy. Analyzing survival by individual high-risk criteria revealed significantly improved survival for those patients with elevated beta-human chorionic gonadotropin titer alone when compared with all other high-risk criteria. Fifty-eight percent of patients (14 of 24) primarily treated with alternating-sequential therapy consisting of methotrexate and actinomycin-D experienced a complete remission. Of those patients primarily treated with methotrexate, actinomycin-D, and cyclophosphamide, 63% (20 of 32) achieved a complete remission. Treatment with second-line chemotherapy was largely unsuccessful. Aggressive early treatment is warranted in this group of patients, using multiagent chemotherapy. A search for newer more effective regimens should continue.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003609 Dactinomycin A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) Actinomycin,Actinomycin D,Meractinomycin,Cosmegen,Cosmegen Lyovac,Lyovac-Cosmegen,Lyovac Cosmegen,Lyovac, Cosmegen,LyovacCosmegen
D005260 Female Females
D006063 Chorionic Gonadotropin A gonadotropic glycoprotein hormone produced primarily by the PLACENTA. Similar to the pituitary LUTEINIZING HORMONE in structure and function, chorionic gonadotropin is involved in maintaining the CORPUS LUTEUM during pregnancy. CG consists of two noncovalently linked subunits, alpha and beta. Within a species, the alpha subunit is virtually identical to the alpha subunits of the three pituitary glycoprotein hormones (TSH, LH, and FSH), but the beta subunit is unique and confers its biological specificity (CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN). Chorionic Gonadotropin, Human,HCG (Human Chorionic Gonadotropin),Biogonadil,Choriogonadotropin,Choriogonin,Chorulon,Gonabion,Human Chorionic Gonadotropin,Pregnyl,Gonadotropin, Chorionic,Gonadotropin, Human Chorionic

Related Publications

A N Gordon, and D M Gershenson, and L J Copeland, and P B Saul, and J J Kavanagh, and C L Edwards
Low-risk metastatic gestational trophoblastic disease.
September 1988, Obstetrics and gynecology clinics of North America,
A N Gordon, and D M Gershenson, and L J Copeland, and P B Saul, and J J Kavanagh, and C L Edwards
Analysis of treatment failure in high-risk metastatic gestational trophoblastic disease.
February 1988, Gynecologic oncology,
A N Gordon, and D M Gershenson, and L J Copeland, and P B Saul, and J J Kavanagh, and C L Edwards
High-risk metastatic gestational trophoblastic tumors. Current management.
March 1994, The Journal of reproductive medicine,
A N Gordon, and D M Gershenson, and L J Copeland, and P B Saul, and J J Kavanagh, and C L Edwards
High-risk factors in metastatic gestational trophoblastic neoplasia.
January 1991, The Journal of reproductive medicine,
A N Gordon, and D M Gershenson, and L J Copeland, and P B Saul, and J J Kavanagh, and C L Edwards
High-risk metastatic trophoblastic disease.
September 1988, Obstetrics and gynecology clinics of North America,
A N Gordon, and D M Gershenson, and L J Copeland, and P B Saul, and J J Kavanagh, and C L Edwards
Management of low-risk metastatic gestational trophoblastic disease.
April 1981, The Journal of reproductive medicine,
A N Gordon, and D M Gershenson, and L J Copeland, and P B Saul, and J J Kavanagh, and C L Edwards
Management of high-risk gestational trophoblastic disease.
September 1987, The Journal of reproductive medicine,
A N Gordon, and D M Gershenson, and L J Copeland, and P B Saul, and J J Kavanagh, and C L Edwards
Management of high-risk gestational trophoblastic disease.
January 1998, The Journal of reproductive medicine,
A N Gordon, and D M Gershenson, and L J Copeland, and P B Saul, and J J Kavanagh, and C L Edwards
Current management of low-risk metastatic gestational trophoblastic disease.
September 1987, The Journal of reproductive medicine,
A N Gordon, and D M Gershenson, and L J Copeland, and P B Saul, and J J Kavanagh, and C L Edwards
High-risk metastatic gestational trophoblastic disease. A new dose-intensive, multiagent chemotherapeutic regimen.
January 1991, The Journal of reproductive medicine,
Copied contents to your clipboard!